Evidence map›Paper›PMID 38281136›Full record

ArticleACS infectious diseases2024

Heterologous Sarbecovirus Receptor Binding Domains as Scaffolds for SARS-CoV-2 Receptor Binding Motif Presentation.

Blake M Hauser, Maya Sangesland, Evan C Lam, Kerri J St Denis, Maegan L Sheehan, Mya L Vu, Agnes H Cheng, Sophia Sordilla, Dana Thornlow Lamson, Ahmad W Almawi and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Blake M HauserRagon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States.
Maya SangeslandRagon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States.
Evan C LamRagon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States.
Kerri J St DenisRagon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States.
Maegan L SheehanRagon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States.
Mya L VuRagon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States.
Agnes H ChengRagon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States.
Sophia SordillaRagon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States.
Dana Thornlow LamsonRagon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States.
Ahmad W AlmawiCenter for Molecular Interactions, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, United States.
Alejandro B BalazsRagon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States.
Daniel LingwoodRagon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States.ORCID 0000-0001-5631-9238
Aaron G SchmidtRagon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States.ORCID 0000-0003-3627-2553
Ragon Institute of MGH, MIT and Harvard · USHarvard University · US

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
The Development and Evaluation of Pan-Coronavirus VaccinesP01AI168347 · NIAID · WASHINGTON UNIVERSITY · PI Matthew Bryan Frieman · 2022 to 2026
$15.9M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Epitope focusing to the receptor binding motif for a universal coronavirus vaccineR01AI146779 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SCHMIDT, AARON GREGORY · 2019 to 2023
$4.2M
Innate-like BCR activity as a template for universal vaccination against influenza virusR01AI137057 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHACKERIAN, BRYCE C, LINGWOOD, DANIEL · 2018 to 2022
$2.6M
Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
Triggering germline-encoded broadly neutralizing antibody responses against influenza virusR01AI153098 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BATISTA, FACUNDO DAMIAN, LINGWOOD, DANIEL · 2020 to 2023
$2.1M
Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesisR01AI155447 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2021 to 2025
$2.0M
AAV Vectored Delivery of Broadly Neutralizing Antibodies with Optimal Innate Functionality Against HIVR01AI174875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2023 to 2024
$1.6M
Epitope focusing using structure-based immunogen design approachesF30AI160908 · NIAID · HARVARD MEDICAL SCHOOL · PI HAUSER, BLAKE MARIE · 2021 to 2023
$91k
NIAID NIH HHS F30 AI160908NIAID NIH HHS P01 AI168347NIAID NIH HHS R01 AI137057NIAID NIH HHS R01 AI146779NIAID NIH HHS R01 AI153098NIAID NIH HHS R01 AI155447NIAID NIH HHS R01 AI174875NIDA NIH HHS DP2 DA040254NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Structure-guided rational immunogen design can generate optimized immunogens that elicit a desired humoral response. Design strategies often center on targeting conserved sites on viral glycoproteins that will ultimately confer potent neutralization. For SARS-CoV-2 (SARS-2), the surface-exposed spike glycoprotein includes a broadly conserved portion, the receptor binding motif (RBM), that is required to engage the host cellular receptor, ACE2. Expanding humoral responses to this site may result in a more potent neutralizing antibody response against diverse sarbecoviruses. Here, we used a "resurfacing" approach and iterative design cycles to graft the SARS-2 RBM onto heterologous sarbecovirus scaffolds. The scaffolds were selected to vary the antigenic distance relative to SARS-2 to potentially focus responses to RBM. Multimerized versions of these immunogens elicited broad neutralization against sarbecoviruses in the context of preexisting SARS-2 immunity. These validated engineering approaches can help inform future immunogen design efforts for sarbecoviruses and are generally applicable to other viruses.

Indexed as

COVID-19Severe acute respiratory syndrome-related coronavirusAntibodies, NeutralizingHumansSARS-CoV-2Antibodies, Neutralizingcoronavirusimmune imprintingSARS-CoV-2

Identifiers

PMID38281136
PMCPMC10862550
OpenAlexW4391289923

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.